Previous 10 | Next 10 |
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report first quarter 2020 financial results and provide a business update on Thursday, May 7, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m...
Management to Host Conference Call / Webcast with Bronchiectasis Expert Dr. James Chalmers Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the Company has entered into an exclusive license and collaboration agreement with Grifols for Apulmiq (inhaled lipo...
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on the impact COVID-19 has had on two of the Company’s clinical studies in cystic fibrosis (CF). Due to the COVID-19 pandemic, and out of an abundance of caution for people living with CF and clinical ...
Savara Inc. (SVRA) Q4 2019 Earnings Conference Call March 12, 2020 4:30 PM ET Company Participants Anne Erickson - Vice President of Investor Relations and Corporate Communications Rob Neville - Chief Executive Officer Badrul Chowdhury - Chief Medical Officer Taneli Jouhikainen...
Savara (NASDAQ: SVRA ): Q4 GAAP EPS of -$0.72 misses by $0.31 . Cash and equivalents $121.8M. Press Release More news on: Savara Inc., Earnings news and commentary, Healthcare stocks news, ,
Announced Positive Results from IMPALA Open-Label Follow-Up Period That Demonstrate Continued Improvement After Longer Term Exposure to Molgradex Company Planning an Additional Phase 3 Study of Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) ...
Gainers: aTyr Pharma (NASDAQ: LIFE ) +48% . More news on: aTyr Pharma, Inc., Mechel PAO, The Habit Restaurants, Inc., Stocks on the move, Read more ...
Gainers: Savara (NASDAQ: SVRA ) +98% . More news on: Savara Inc., NIO Limited, Sol-Gel Technologies Ltd., Stocks on the move, Read more ...
Sol-Gel Technologies (NASDAQ: SLGL ) +160% on Twyneo successful in acne studies. More news on: Sol-Gel Technologies Ltd., Savara Inc., NIO Limited, Stocks on the move, Read more ...
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for...
News, Short Squeeze, Breakout and More Instantly...
Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a ra...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fir...
Savara’s Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned Experts Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage ...